Drug Profile


Alternative Names: 17-Alpha estradiol; 17-α estradiol; Estrogen analogue - MIGENIX; MITO-4509; MX-4509

Latest Information Update: 08 Apr 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MIGENIX
  • Class Antidementias; Antiparkinsonians; Estradiol congeners; Neuroprotectants; Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease; Friedreich's ataxia; Neurodegenerative disorders; Parkinson's disease

Most Recent Events

  • 14 Dec 2005 A clinical study has been added to the adverse events and pharmacokinetics sections
  • 28 Apr 2005 MIGENIX receives clearance from Health Canada to conduct a phase I/II trial for Alzheimer's disease in Canada
  • 23 Feb 2005 Phase-I clinical trials in Alzheimer's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top